25 XP   0   0   10

Jazz Pharmaceuticals PLC
Buy, Hold or Sell?

Let's analyse Jazz Pharmaceuticals PLC together

PenkeI guess you are interested in Jazz Pharmaceuticals PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jazz Pharmaceuticals PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Jazz Pharmaceuticals PLC

I send you an email if I find something interesting about Jazz Pharmaceuticals PLC.

Quick analysis of Jazz Pharmaceuticals PLC (30 sec.)










What can you expect buying and holding a share of Jazz Pharmaceuticals PLC? (30 sec.)

How much money do you get?

How much money do you get?
$1.53
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$53.64
Expected worth in 1 year
$58.33
How sure are you?
75.0%

+ What do you gain per year?

Total Gains per Share
$6.22
Return On Investment
5.8%

For what price can you sell your share?

Current Price per Share
$107.43
Expected price per share
$106.61 - $115.45
How sure are you?
50%

1. Valuation of Jazz Pharmaceuticals PLC (5 min.)




Live pricePrice per Share (EOD)

$107.43

Intrinsic Value Per Share

$66.44 - $128.96

Total Value Per Share

$120.08 - $182.60

2. Growth of Jazz Pharmaceuticals PLC (5 min.)




Is Jazz Pharmaceuticals PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7b$3.1b$361.7m10.3%

How much money is Jazz Pharmaceuticals PLC making?

Current yearPrevious yearGrowGrow %
Making money$103.7m-$54.1m$157.8m152.2%
Net Profit Margin10.8%-5.5%--

How much money comes from the company's main activities?

3. Financial Health of Jazz Pharmaceuticals PLC (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#21 / 1010

Most Revenue
#19 / 1010

Most Profit
#28 / 1010

Most Efficient
#107 / 1010

What can you expect buying and holding a share of Jazz Pharmaceuticals PLC? (5 min.)

Welcome investor! Jazz Pharmaceuticals PLC's management wants to use your money to grow the business. In return you get a share of Jazz Pharmaceuticals PLC.

What can you expect buying and holding a share of Jazz Pharmaceuticals PLC?

First you should know what it really means to hold a share of Jazz Pharmaceuticals PLC. And how you can make/lose money.

Speculation

The Price per Share of Jazz Pharmaceuticals PLC is $107.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jazz Pharmaceuticals PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jazz Pharmaceuticals PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $53.64. Based on the TTM, the Book Value Change Per Share is $1.17 per quarter. Based on the YOY, the Book Value Change Per Share is $-3.67 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.38 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jazz Pharmaceuticals PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps1.351.3%1.441.3%-0.89-0.8%0.460.4%0.920.9%
Usd Book Value Change Per Share4.694.4%1.171.1%-3.67-3.4%0.470.4%0.820.8%
Usd Dividend Per Share0.000.0%0.380.4%0.180.2%0.110.1%0.060.1%
Usd Total Gains Per Share4.694.4%1.561.4%-3.48-3.2%0.580.5%0.880.8%
Usd Price Per Share123.00-130.69-151.07-140.36-143.47-
Price to Earnings Ratio22.75-24.79-360.23-79.20-53.74-
Price-to-Total Gains Ratio26.21-33.86--10.01-25.71-78.65-
Price to Book Ratio2.29-2.69-3.03-2.70-3.93-
Price-to-Total Gains Ratio26.21-33.86--10.01-25.71-78.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share107.43
Number of shares9
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.380.11
Usd Book Value Change Per Share1.170.47
Usd Total Gains Per Share1.560.58
Gains per Quarter (9 shares)14.015.25
Gains per Year (9 shares)56.0221.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
114424641711
2288510283432
341127158125153
455169214166874
569211270208595
68325432624102116
79629638228119137
811033843833135158
912438049437152179
1013842355041169200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%7.05.00.058.3%14.06.00.070.0%33.07.00.082.5%51.020.00.071.8%
Book Value Change Per Share3.01.00.075.0%7.05.00.058.3%13.07.00.065.0%30.010.00.075.0%52.018.01.073.2%
Dividend per Share3.00.01.075.0%5.00.07.041.7%5.00.015.025.0%5.00.035.012.5%6.00.065.08.5%
Total Gains per Share3.01.00.075.0%7.05.00.058.3%13.07.00.065.0%30.010.00.075.0%52.018.01.073.2%

Fundamentals of Jazz Pharmaceuticals PLC

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Fundamental data was last updated by Penke on 2024-04-11 12:24:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Jazz Pharmaceuticals PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jazz Pharmaceuticals PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 9.3% means that $0.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 9.3%. The company is making a profit. +1
  • The TTM is 10.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ9.3%TTM10.8%-1.5%
TTM10.8%YOY-5.5%+16.3%
TTM10.8%5Y5.8%+5.0%
5Y5.8%10Y13.6%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3%-207.2%+216.5%
TTM10.8%-216.8%+227.6%
YOY-5.5%-282.3%+276.8%
5Y5.8%-436.8%+442.6%
10Y13.6%-597.3%+610.9%
1.1.2. Return on Assets

Shows how efficient Jazz Pharmaceuticals PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • 0.8% Return on Assets means that Jazz Pharmaceuticals PLC generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.9%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.9%-0.1%
TTM0.9%YOY-0.5%+1.4%
TTM0.9%5Y0.6%+0.3%
5Y0.6%10Y1.3%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8%-13.3%+14.1%
TTM0.9%-12.8%+13.7%
YOY-0.5%-11.6%+11.1%
5Y0.6%-13.8%+14.4%
10Y1.3%-15.6%+16.9%
1.1.3. Return on Equity

Shows how efficient Jazz Pharmaceuticals PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • 2.5% Return on Equity means Jazz Pharmaceuticals PLC generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 2.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.5%TTM2.9%-0.4%
TTM2.9%YOY-1.8%+4.7%
TTM2.9%5Y1.0%+1.9%
5Y1.0%10Y2.6%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5%-16.9%+19.4%
TTM2.9%-16.1%+19.0%
YOY-1.8%-14.9%+13.1%
5Y1.0%-19.3%+20.3%
10Y2.6%-20.1%+22.7%

1.2. Operating Efficiency of Jazz Pharmaceuticals PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jazz Pharmaceuticals PLC is operating .

  • Measures how much profit Jazz Pharmaceuticals PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • An Operating Margin of 20.0% means the company generated $0.20  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 20.0%. The company is operating efficient. +1
  • The TTM is 17.1%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ20.0%TTM17.1%+2.9%
TTM17.1%YOY13.9%+3.2%
TTM17.1%5Y20.0%-3.0%
5Y20.0%10Y29.1%-9.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.0%-298.0%+318.0%
TTM17.1%-238.5%+255.6%
YOY13.9%-288.4%+302.3%
5Y20.0%-486.2%+506.2%
10Y29.1%-628.4%+657.5%
1.2.2. Operating Ratio

Measures how efficient Jazz Pharmaceuticals PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.80 means that the operating costs are $0.80 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 0.800. The company is less efficient in keeping operating costs low.
  • The TTM is 0.829. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.800TTM0.829-0.029
TTM0.829YOY0.861-0.032
TTM0.8295Y0.800+0.029
5Y0.80010Y0.709+0.091
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8003.235-2.435
TTM0.8293.310-2.481
YOY0.8613.838-2.977
5Y0.8005.679-4.879
10Y0.7097.823-7.114

1.3. Liquidity of Jazz Pharmaceuticals PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jazz Pharmaceuticals PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.12 means the company has $2.12 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 2.124. The company is able to pay all its short-term debts. +1
  • The TTM is 2.609. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.124TTM2.609-0.485
TTM2.609YOY3.255-0.646
TTM2.6095Y3.541-0.932
5Y3.54110Y3.615-0.074
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1243.863-1.739
TTM2.6094.169-1.560
YOY3.2555.337-2.082
5Y3.5416.122-2.581
10Y3.6156.434-2.819
1.3.2. Quick Ratio

Measures if Jazz Pharmaceuticals PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • A Quick Ratio of 1.79 means the company can pay off $1.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 1.791. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.924. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.791TTM1.924-0.134
TTM1.924YOY1.764+0.160
TTM1.9245Y3.116-1.192
5Y3.11610Y3.373-0.257
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7913.504-1.713
TTM1.9243.991-2.067
YOY1.7645.371-3.607
5Y3.1166.088-2.972
10Y3.3736.395-3.022

1.4. Solvency of Jazz Pharmaceuticals PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jazz Pharmaceuticals PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jazz Pharmaceuticals PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.67 means that Jazz Pharmaceuticals PLC assets are financed with 67.2% credit (debt) and the remaining percentage (100% - 67.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 0.672. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.686. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.672TTM0.686-0.014
TTM0.686YOY0.715-0.028
TTM0.6865Y0.588+0.098
5Y0.58810Y0.567+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6720.339+0.333
TTM0.6860.337+0.349
YOY0.7150.271+0.444
5Y0.5880.368+0.220
10Y0.5670.388+0.179
1.4.2. Debt to Equity Ratio

Measures if Jazz Pharmaceuticals PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 204.9% means that company has $2.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jazz Pharmaceuticals PLC:

  • The MRQ is 2.049. The company is just not able to pay all its debts with equity.
  • The TTM is 2.192. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.049TTM2.192-0.143
TTM2.192YOY2.514-0.322
TTM2.1925Y1.643+0.548
5Y1.64310Y1.440+0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0490.392+1.657
TTM2.1920.403+1.789
YOY2.5140.335+2.179
5Y1.6430.427+1.216
10Y1.4400.461+0.979

2. Market Valuation of Jazz Pharmaceuticals PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Jazz Pharmaceuticals PLC generates.

  • Above 15 is considered overpriced but always compare Jazz Pharmaceuticals PLC to the Biotechnology industry mean.
  • A PE ratio of 22.75 means the investor is paying $22.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jazz Pharmaceuticals PLC:

  • The EOD is 19.874. Based on the earnings, the company is fair priced.
  • The MRQ is 22.755. Based on the earnings, the company is fair priced.
  • The TTM is 24.792. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD19.874MRQ22.755-2.880
MRQ22.755TTM24.792-2.037
TTM24.792YOY360.226-335.434
TTM24.7925Y79.195-54.404
5Y79.19510Y53.738+25.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD19.874-2.300+22.174
MRQ22.755-2.656+25.411
TTM24.792-2.718+27.510
YOY360.226-4.145+364.371
5Y79.195-6.258+85.453
10Y53.738-6.315+60.053
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jazz Pharmaceuticals PLC:

  • The EOD is 11.901. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 13.626. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 9.404. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD11.901MRQ13.626-1.725
MRQ13.626TTM9.404+4.221
TTM9.404YOY-7.212+16.616
TTM9.4045Y13.484-4.080
5Y13.48410Y12.782+0.702
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.901-2.974+14.875
MRQ13.626-3.306+16.932
TTM9.404-3.508+12.912
YOY-7.212-5.613-1.599
5Y13.484-8.378+21.862
10Y12.782-8.873+21.655
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jazz Pharmaceuticals PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.29 means the investor is paying $2.29 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Jazz Pharmaceuticals PLC:

  • The EOD is 2.003. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.293. Based on the equity, the company is underpriced. +1
  • The TTM is 2.690. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.003MRQ2.293-0.290
MRQ2.293TTM2.690-0.397
TTM2.690YOY3.027-0.337
TTM2.6905Y2.701-0.010
5Y2.70110Y3.935-1.234
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0031.914+0.089
MRQ2.2932.116+0.177
TTM2.6902.097+0.593
YOY3.0272.881+0.146
5Y2.7013.550-0.849
10Y3.9353.936-0.001
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Jazz Pharmaceuticals PLC.

3.1. Institutions holding Jazz Pharmaceuticals PLC

Institutions are holding 95.735% of the shares of Jazz Pharmaceuticals PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc11.31770.02217056032-130845-1.8206
2023-12-31Vanguard Group Inc10.20730.01716363748-15305-0.2399
2023-12-31State Street Corporation3.88340.01452421125960774.1323
2023-12-31LSV Asset Management3.75850.62892343227-28950-1.2204
2023-12-31JPMorgan Chase & Co2.24120.01651397284-28757-2.0166
2023-12-31Ameriprise Financial Inc2.10560.04831312771131591.0125
2023-12-31Wellington Management Company LLP2.05340.02941280197-388314-23.2731
2023-12-31Polaris Capital Management, LLC2.0337.52961267460271002.1848
2023-12-31Renaissance Technologies Corp1.97540.23451231574-76041-5.8152
2023-12-31FMR Inc1.97130.01161228991-104138-7.8115
2023-12-31Geode Capital Management, LLC1.68320.01351049388366413.618
2023-12-31Pacer Advisors, INC.1.6420.3564102370622486528.1489
2023-12-31EcoR1 Capital, LLC1.62633.23811013952645541175.2231
2023-12-31Franklin Resources Inc1.40750.0505877509-157114-15.1856
2023-12-31Baupost Group LLC1.33722.236583369616000023.7496
2023-12-31Morgan Stanley - Brokerage Accounts1.24920.0084778803-37014-4.537
2023-12-31Dimensional Fund Advisors, Inc.1.22840.0275765846-29766-3.7413
2023-12-31Vestal Point Capital LP1.16299.44697250007250000
2023-12-31BNP Paribas Investment Partners SA1.14330.2442712811-50275-6.5884
2023-12-31Camber Capital Management LLC1.08272.11596750006750000
Total 55.109526.290434358120+1556864+4.5%

3.2. Funds holding Jazz Pharmaceuticals PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28iShares Core S&P Mid-Cap ETF3.14110.27731958345-1696-0.0865
2024-02-29Vanguard Total Stock Mkt Idx Inv3.0320.01451890340-4542-0.2397
2024-02-29Vanguard Small Cap Index2.47260.13041541559142220.9312
2024-03-28Pacer US Cash Cows 100 ETF2.05420.683128071822960.1796
2024-02-29Vanguard Small Cap Value Index Inv1.68670.2351105156852260.4995
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.49280.108493070217650.19
2024-02-29JPMorgan Mid Cap Value L1.40060.770587320500
2023-12-31JPM US Mid Cap Value-Composite1.40060.8164873205-16807-1.8884
2024-03-31Pear Tree Polaris Foreign Value Ord0.82162.01045122009550022.9182
2024-02-29SPDR® S&P MIDCAP 400 ETF Trust0.80650.284350283818900.3773
2023-12-31Polaris Capital Mgt Polaris Intl Eq0.68241.649742546044001.045
2024-02-29BNP Paribas Health Cr Innovtr Cl Cap0.63512.71753959332730.069
2024-02-29Franklin Biotechnology Discv A(acc)USD0.63492.550139583100
2024-02-29Hartford MidCap Y0.6330.7232394633-7414-1.8441
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.59830.1062373009131003.6398
2024-02-29Fidelity Extended Market Index0.57080.110335589623260.6579
2024-02-29Columbia VP Overseas Core 30.55931.181134872800
2023-12-31Columbia EAFE Core0.55931.1925348728-13179-3.6415
2024-03-31Swedbank Robur Transfer 800.54560.560434014100
2024-02-29Columbia Overseas Value Inst0.51011.307831804600
Total 24.237517.429115111085+97360+0.6%

3.3. Insider Transactions

Insiders are holding 2.818% of the shares of Jazz Pharmaceuticals PLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-06Patricia CarrSELL1936119.64
2024-03-01Philip L JohnsonBUY12000119.65
2023-12-04Mark Douglas SmithSELL417119.27
2023-09-01Neena M PatilSELL1500144.25
2023-08-29Patricia CarrSELL142143.47
2023-08-15Neena M PatilSELL750139.59
2023-08-14Patricia CarrSELL158138.16
2023-08-14Rick E WinninghamSELL1241138.16
2023-06-07Patricia CarrSELL126127.92
2023-06-01Neena M PatilSELL1600127.98
2023-05-18Renee D GalaSELL6000131.75

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Jazz Pharmaceuticals PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.6921.174+300%-3.665+178%0.470+897%0.821+471%
Book Value Per Share--53.63648.933+10%50.122+7%52.451+2%41.778+28%
Current Ratio--2.1242.609-19%3.255-35%3.541-40%3.615-41%
Debt To Asset Ratio--0.6720.686-2%0.715-6%0.588+14%0.567+19%
Debt To Equity Ratio--2.0492.192-7%2.514-18%1.643+25%1.440+42%
Dividend Per Share---0.382-100%0.183-100%0.113-100%0.056-100%
Eps--1.3511.443-6%-0.890+166%0.457+195%0.916+47%
Free Cash Flow Per Share--2.2573.686-39%3.071-27%2.833-20%2.343-4%
Free Cash Flow To Equity Per Share--0.8172.621-69%0.964-15%5.571-85%3.773-78%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--128.963--------
Intrinsic Value_10Y_min--66.444--------
Intrinsic Value_1Y_max--12.946--------
Intrinsic Value_1Y_min--8.969--------
Intrinsic Value_3Y_max--38.881--------
Intrinsic Value_3Y_min--25.107--------
Intrinsic Value_5Y_max--64.794--------
Intrinsic Value_5Y_min--39.102--------
Market Cap6697755579.000-28%8569779000.0009427402287.500-9%9525507442.500-10%9028428807.550-5%9098434511.100-6%
Net Profit Margin--0.0930.108-14%-0.055+159%0.058+61%0.136-31%
Operating Margin--0.2000.171+17%0.139+44%0.2000%0.291-31%
Operating Ratio--0.8000.829-3%0.861-7%0.800+0%0.709+13%
Pb Ratio2.003-14%2.2932.690-15%3.027-24%2.701-15%3.935-42%
Pe Ratio19.874-14%22.75524.792-8%360.226-94%79.195-71%53.738-58%
Price Per Share107.430-14%123.000130.685-6%151.070-19%140.365-12%143.470-14%
Price To Free Cash Flow Ratio11.901-14%13.6269.404+45%-7.212+153%13.484+1%12.782+7%
Price To Total Gains Ratio22.896-14%26.21433.858-23%-10.015+138%25.709+2%78.652-67%
Quick Ratio--1.7911.924-7%1.764+2%3.116-43%3.373-47%
Return On Assets--0.0080.009-10%-0.005+161%0.006+29%0.013-36%
Return On Equity--0.0250.029-14%-0.018+171%0.010+146%0.026-4%
Total Gains Per Share--4.6921.556+202%-3.482+174%0.583+704%0.878+434%
Usd Book Value--3736997000.0003521771500.000+6%3160049000.000+18%3371332350.000+11%2657526325.000+41%
Usd Book Value Change Per Share--4.6921.174+300%-3.665+178%0.470+897%0.821+471%
Usd Book Value Per Share--53.63648.933+10%50.122+7%52.451+2%41.778+28%
Usd Dividend Per Share---0.382-100%0.183-100%0.113-100%0.056-100%
Usd Eps--1.3511.443-6%-0.890+166%0.457+195%0.916+47%
Usd Free Cash Flow--157237000.000266761250.000-41%193445750.000-19%184413150.000-15%150164125.000+5%
Usd Free Cash Flow Per Share--2.2573.686-39%3.071-27%2.833-20%2.343-4%
Usd Free Cash Flow To Equity Per Share--0.8172.621-69%0.964-15%5.571-85%3.773-78%
Usd Market Cap6697755579.000-28%8569779000.0009427402287.500-9%9525507442.500-10%9028428807.550-5%9098434511.100-6%
Usd Price Per Share107.430-14%123.000130.685-6%151.070-19%140.365-12%143.470-14%
Usd Profit--94154000.000103708000.000-9%-54150000.000+158%31527350.000+199%58566300.000+61%
Usd Revenue--1011935000.000958551000.000+6%914843500.000+11%755657200.000+34%565210250.000+79%
Usd Total Gains Per Share--4.6921.556+202%-3.482+174%0.583+704%0.878+434%
 EOD+4 -4MRQTTM+15 -20YOY+23 -125Y+18 -1710Y+15 -20

4.2. Fundamental Score

Let's check the fundamental score of Jazz Pharmaceuticals PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1519.874
Price to Book Ratio (EOD)Between0-12.003
Net Profit Margin (MRQ)Greater than00.093
Operating Margin (MRQ)Greater than00.200
Quick Ratio (MRQ)Greater than11.791
Current Ratio (MRQ)Greater than12.124
Debt to Asset Ratio (MRQ)Less than10.672
Debt to Equity Ratio (MRQ)Less than12.049
Return on Equity (MRQ)Greater than0.150.025
Return on Assets (MRQ)Greater than0.050.008
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Jazz Pharmaceuticals PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.215
Ma 20Greater thanMa 50112.656
Ma 50Greater thanMa 100118.634
Ma 100Greater thanMa 200120.370
OpenGreater thanClose108.250
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets11,393,359
Total Liabilities7,656,362
Total Stockholder Equity3,736,997
 As reported
Total Liabilities 7,656,362
Total Stockholder Equity+ 3,736,997
Total Assets = 11,393,359

Assets

Total Assets11,393,359
Total Current Assets3,263,921
Long-term Assets8,129,438
Total Current Assets
Cash And Cash Equivalents 1,206,310
Short-term Investments 420,000
Net Receivables 705,794
Inventory 597,039
Other Current Assets 334,778
Total Current Assets  (as reported)3,263,921
Total Current Assets  (calculated)3,263,921
+/-0
Long-term Assets
Property Plant Equipment 234,986
Goodwill 1,753,130
Intangible Assets 5,418,039
Long-term Assets Other 240,749
Long-term Assets  (as reported)8,129,438
Long-term Assets  (calculated)7,646,904
+/- 482,534

Liabilities & Shareholders' Equity

Total Current Liabilities1,536,692
Long-term Liabilities6,119,670
Total Stockholder Equity3,736,997
Total Current Liabilities
Short-term Debt 624,401
Short Long Term Debt 604,954
Accounts payable 102,750
Other Current Liabilities 774,467
Total Current Liabilities  (as reported)1,536,692
Total Current Liabilities  (calculated)2,106,572
+/- 569,880
Long-term Liabilities
Long term Debt 5,107,988
Capital Lease Obligations 78,672
Long-term Liabilities Other 104,751
Long-term Liabilities  (as reported)6,119,670
Long-term Liabilities  (calculated)5,291,411
+/- 828,259
Total Stockholder Equity
Common Stock61
Retained Earnings 878,656
Accumulated Other Comprehensive Income -841,674
Other Stockholders Equity 3,699,954
Total Stockholder Equity (as reported)3,736,997
Total Stockholder Equity (calculated)3,736,997
+/-0
Other
Capital Stock61
Cash and Short Term Investments 1,626,310
Common Stock Shares Outstanding 69,673
Current Deferred Revenue35,074
Liabilities and Stockholders Equity 11,393,359
Net Debt 4,590,343
Net Invested Capital 9,449,939
Net Working Capital 1,898,736
Property Plant and Equipment Gross 368,337
Short Long Term Debt Total 5,796,653



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-31
> Total Assets 
0
0
0
164,781
0
0
0
214,571
197,910
276,870
258,767
207,554
239,018
186,591
179,793
117,498
109,937
108,574
102,172
107,396
106,706
97,264
108,000
135,729
154,178
193,409
207,813
253,573
895,360
1,697,944
1,726,699
1,966,493
2,009,690
2,093,880
2,185,499
2,238,221
3,196,434
3,155,749
3,347,536
3,338,955
3,237,593
3,393,274
3,464,300
3,359,663
3,534,979
3,448,094
4,930,581
4,800,227
4,815,824
4,804,024
4,999,024
5,123,672
5,287,128
5,348,967
5,485,788
5,203,491
5,280,235
5,488,661
5,527,850
5,538,897
5,215,295
6,066,501
6,291,958
6,535,901
6,756,470
13,212,993
12,478,152
12,298,639
11,768,917
11,200,133
10,384,667
10,835,255
11,047,125
11,260,540
11,204,065
11,393,359
11,393,35911,204,06511,260,54011,047,12510,835,25510,384,66711,200,13311,768,91712,298,63912,478,15213,212,9936,756,4706,535,9016,291,9586,066,5015,215,2955,538,8975,527,8505,488,6615,280,2355,203,4915,485,7885,348,9675,287,1285,123,6724,999,0244,804,0244,815,8244,800,2274,930,5813,448,0943,534,9793,359,6633,464,3003,393,2743,237,5933,338,9553,347,5363,155,7493,196,4342,238,2212,185,4992,093,8802,009,6901,966,4931,726,6991,697,944895,360253,573207,813193,409154,178135,729108,00097,264106,706107,396102,172108,574109,937117,498179,793186,591239,018207,554258,767276,870197,910214,571000164,781000
   > Total Current Assets 
0
0
0
31,384
0
0
0
91,563
79,266
161,155
144,978
116,091
119,245
70,196
69,704
43,999
33,544
32,725
29,144
36,954
38,742
32,083
44,800
74,458
94,840
136,088
152,140
199,131
327,140
300,442
385,012
551,572
647,372
734,176
810,067
864,617
517,320
544,912
878,520
1,015,845
1,102,935
1,244,910
1,314,943
1,257,667
1,270,618
1,230,890
744,229
748,069
752,853
662,504
830,944
968,277
1,126,321
1,306,931
1,464,389
1,234,005
1,305,617
1,370,066
1,520,556
1,630,268
1,517,637
2,302,346
2,555,573
2,839,568
3,166,896
2,953,964
2,628,226
2,611,334
2,500,856
2,590,833
2,571,504
2,606,140
2,784,650
3,009,855
3,245,752
3,263,921
3,263,9213,245,7523,009,8552,784,6502,606,1402,571,5042,590,8332,500,8562,611,3342,628,2262,953,9643,166,8962,839,5682,555,5732,302,3461,517,6371,630,2681,520,5561,370,0661,305,6171,234,0051,464,3891,306,9311,126,321968,277830,944662,504752,853748,069744,2291,230,8901,270,6181,257,6671,314,9431,244,9101,102,9351,015,845878,520544,912517,320864,617810,067734,176647,372551,572385,012300,442327,140199,131152,140136,08894,84074,45844,80032,08338,74236,95429,14432,72533,54443,99969,70470,196119,245116,091144,978161,15579,26691,56300031,384000
       Cash And Cash Equivalents 
0
0
0
20,614
0
0
0
78,948
67,667
148,000
119,972
102,945
100,771
51,202
49,907
24,903
17,015
15,772
12,230
15,595
18,998
9,574
22,900
44,794
65,061
102,396
101,215
82,076
170,654
154,543
189,793
387,196
450,511
504,307
588,462
636,504
245,874
268,255
575,040
684,042
782,603
921,643
998,859
988,785
979,780
867,966
366,567
365,963
346,995
239,213
252,615
386,035
453,169
485,081
499,018
309,622
547,466
637,739
795,175
637,344
701,602
786,082
741,942
1,057,769
2,097,533
891,400
671,780
591,448
490,835
711,265
839,358
881,482
1,167,911
1,282,304
1,335,690
1,206,310
1,206,3101,335,6901,282,3041,167,911881,482839,358711,265490,835591,448671,780891,4002,097,5331,057,769741,942786,082701,602637,344795,175637,739547,466309,622499,018485,081453,169386,035252,615239,213346,995365,963366,567867,966979,780988,785998,859921,643782,603684,042575,040268,255245,874636,504588,462504,307450,511387,196189,793154,543170,65482,076101,215102,39665,06144,79422,9009,57418,99815,59512,23015,77217,01524,90349,90751,202100,771102,945119,972148,00067,66778,94800020,614000
       Short-term Investments 
0
0
0
300
0
0
0
275
275
12,085
10,939
12,000
4,410
1,500
999
1,004
1,000
1,075
950
2,988
951
910
400
400
400
0
12,133
75,822
73,564
0
0
0
0
0
0
0
5,502
0
0
0
0
0
0
0
764
48,409
59,418
60,000
60,000
80,000
200,000
215,000
255,000
330,000
565,000
515,000
285,000
245,000
275,000
440,000
280,000
910,000
1,175,000
1,075,000
335,000
0
0
0
0
60,000
60,000
30,000
180,000
80,000
250,000
420,000
420,000250,00080,000180,00030,00060,00060,0000000335,0001,075,0001,175,000910,000280,000440,000275,000245,000285,000515,000565,000330,000255,000215,000200,00080,00060,00060,00059,41848,40976400000005,502000000073,56475,82212,13304004004009109512,9889501,0751,0001,0049991,5004,41012,00010,93912,085275275000300000
       Net Receivables 
0
0
0
3,597
0
0
0
5,380
6,167
6,462
6,566
5,389
5,310
5,221
6,686
6,643
7,012
9,197
9,202
12,313
11,955
14,095
14,100
22,081
21,383
24,999
31,428
34,374
56,143
78,130
88,304
75,480
93,833
114,075
113,271
124,805
154,986
160,775
187,604
186,371
189,682
193,647
195,816
209,685
223,802
231,837
238,072
234,244
243,035
238,752
258,616
224,129
281,424
278,441
279,437
263,838
320,485
311,249
267,031
355,987
317,301
351,920
361,664
396,490
413,976
506,660
499,023
563,360
572,392
594,034
601,179
651,493
623,938
610,389
627,841
705,794
705,794627,841610,389623,938651,493601,179594,034572,392563,360499,023506,660413,976396,490361,664351,920317,301355,987267,031311,249320,485263,838279,437278,441281,424224,129258,616238,752243,035234,244238,072231,837223,802209,685195,816193,647189,682186,371187,604160,775154,986124,805113,271114,07593,83375,48088,30478,13056,14334,37431,42824,99921,38322,08114,10014,09511,95512,3139,2029,1977,0126,6436,6865,2215,3105,3896,5666,4626,1675,3800003,597000
       Other Current Assets 
0
0
0
371
0
0
0
487
680
547
1,574
381
1,346
376
736
2,382
2,106
62
261
979
992
788
3,300
279
402
382
532
1,260
4,073
13,508
9,942
19,113
21,395
19,716
18,551
33,843
23,747
18,468
18,362
21,322
21,522
21,985
18,969
19,047
22,431
26,244
24,517
29,310
27,052
36,448
49,120
76,686
62,868
55,634
54,310
67,572
62,985
75,367
81,401
78,895
94,300
112,701
127,258
152,491
147,727
39,365
41,265
252,392
38,655
50,576
45,364
267,192
245,244
72,805
101,395
334,778
334,778101,39572,805245,244267,19245,36450,57638,655252,39241,26539,365147,727152,491127,258112,70194,30078,89581,40175,36762,98567,57254,31055,63462,86876,68649,12036,44827,05229,31024,51726,24422,43119,04718,96921,98521,52221,32218,36218,46823,74733,84318,55119,71621,39519,1139,94213,5084,0731,2605323824022793,300788992979261622,1062,3827363761,3463811,574547680487000371000
   > Long-term Assets 
0
0
0
133,397
0
0
0
123,008
118,644
115,715
113,789
91,463
119,773
116,395
110,089
73,499
76,393
75,849
73,028
70,442
67,964
65,181
63,200
61,271
59,338
57,321
55,673
54,442
568,220
1,397,502
1,341,687
1,414,921
1,362,318
1,359,704
1,375,432
1,373,604
2,679,114
2,610,837
2,469,016
2,323,110
2,134,658
2,148,364
2,149,357
2,101,996
2,264,361
2,217,204
4,186,352
4,052,158
4,062,971
4,141,520
4,168,080
4,155,395
4,160,807
4,042,036
4,021,399
3,969,486
3,974,618
4,118,595
4,007,294
3,908,629
3,697,658
3,764,155
3,736,385
3,696,333
3,589,574
10,259,029
9,849,926
9,687,305
9,268,061
8,609,300
7,813,163
8,229,115
8,262,475
8,250,685
7,958,313
8,129,438
8,129,4387,958,3138,250,6858,262,4758,229,1157,813,1638,609,3009,268,0619,687,3059,849,92610,259,0293,589,5743,696,3333,736,3853,764,1553,697,6583,908,6294,007,2944,118,5953,974,6183,969,4864,021,3994,042,0364,160,8074,155,3954,168,0804,141,5204,062,9714,052,1584,186,3522,217,2042,264,3612,101,9962,149,3572,148,3642,134,6582,323,1102,469,0162,610,8372,679,1141,373,6041,375,4321,359,7041,362,3181,414,9211,341,6871,397,502568,22054,44255,67357,32159,33861,27163,20065,18167,96470,44273,02875,84976,39373,499110,089116,395119,77391,463113,789115,715118,644123,008000133,397000
       Property Plant Equipment 
0
0
0
1,941
0
0
0
2,107
2,116
3,025
3,286
3,941
3,875
4,260
3,708
2,514
2,140
1,778
1,444
1,124
909
901
700
690
652
647
930
1,557
2,026
4,631
6,671
7,281
7,795
10,768
12,060
14,246
30,048
38,462
44,205
58,363
71,283
80,428
83,452
85,572
86,788
93,476
99,898
107,490
119,913
136,626
159,386
170,080
178,920
188,086
198,053
200,358
260,371
271,929
271,350
270,891
265,538
261,438
258,921
257,104
249,601
426,320
344,634
343,423
341,044
317,888
290,067
301,376
303,090
298,304
287,514
234,986
234,986287,514298,304303,090301,376290,067317,888341,044343,423344,634426,320249,601257,104258,921261,438265,538270,891271,350271,929260,371200,358198,053188,086178,920170,080159,386136,626119,913107,49099,89893,47686,78885,57283,45280,42871,28358,36344,20538,46230,04814,24612,06010,7687,7957,2816,6714,6312,0261,5579306476526907009019091,1241,4441,7782,1402,5143,7084,2603,8753,9413,2863,0252,1162,1070001,941000
       Goodwill 
0
0
0
38,883
0
0
0
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,213
38,200
38,213
38,213
38,213
38,213
38,213
239,737
446,236
437,652
442,600
436,355
439,014
446,823
450,456
763,763
760,314
724,388
702,713
654,470
664,015
669,029
657,139
670,991
661,845
927,993
893,810
899,290
926,290
941,428
947,537
960,509
936,493
932,422
927,630
919,972
924,990
906,725
920,018
909,226
918,021
937,099
958,303
938,398
1,887,699
1,849,547
1,827,609
1,782,444
1,687,648
1,592,635
1,692,662
1,723,444
1,742,675
1,705,320
1,753,130
1,753,1301,705,3201,742,6751,723,4441,692,6621,592,6351,687,6481,782,4441,827,6091,849,5471,887,699938,398958,303937,099918,021909,226920,018906,725924,990919,972927,630932,422936,493960,509947,537941,428926,290899,290893,810927,993661,845670,991657,139669,029664,015654,470702,713724,388760,314763,763450,456446,823439,014436,355442,600437,652446,236239,73738,21338,21338,21338,21338,21338,20038,21338,21338,21338,21338,21338,21338,21338,21338,21338,21338,21338,21338,21338,21338,21300038,883000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,138
4,710
5,497
5,674
6,641
5,109
4,500
4,500
4,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000004,5004,5004,5005,1096,6415,6745,4974,7102,138000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
78,740
0
0
0
69,140
63,239
60,952
58,664
36,040
74,919
71,074
65,663
32,526
35,794
33,972
31,915
29,858
27,802
25,757
23,900
22,033
20,171
18,309
16,447
14,585
326,072
927,409
876,959
869,952
835,003
822,976
823,724
812,396
1,755,861
1,680,004
1,550,624
1,437,435
1,284,308
1,282,955
1,270,777
1,185,606
1,348,160
1,300,761
3,110,439
3,012,001
2,998,780
3,033,103
3,019,035
2,979,127
2,953,146
2,842,277
2,787,281
2,731,334
2,679,393
2,687,941
2,593,030
2,440,977
2,238,658
2,286,126
2,241,107
2,195,051
2,108,046
7,588,029
7,282,579
7,152,328
6,783,057
6,237,959
5,570,394
5,794,437
5,764,209
5,705,777
5,417,860
5,418,039
5,418,0395,417,8605,705,7775,764,2095,794,4375,570,3946,237,9596,783,0577,152,3287,282,5797,588,0292,108,0462,195,0512,241,1072,286,1262,238,6582,440,9772,593,0302,687,9412,679,3932,731,3342,787,2812,842,2772,953,1462,979,1273,019,0353,033,1032,998,7803,012,0013,110,4391,300,7611,348,1601,185,6061,270,7771,282,9551,284,3081,437,4351,550,6241,680,0041,755,861812,396823,724822,976835,003869,952876,959927,409326,07214,58516,44718,30920,17122,03323,90025,75727,80229,85831,91533,97235,79432,52665,66371,07474,91936,04058,66460,95263,23969,14000078,740000
       Other Assets 
0
0
0
131,456
0
0
0
120,901
116,528
112,690
110,503
87,522
115,898
112,135
106,381
70,985
74,253
74,071
71,584
69,318
67,055
64,280
62,479
60,581
58,686
56,674
54,743
52,885
566,194
1,392,871
1,335,016
1,407,640
1,354,523
1,348,936
1,363,372
1,359,358
2,649,066
2,572,375
2,424,811
2,264,747
2,063,375
2,067,936
2,065,905
2,016,424
2,177,573
2,123,728
4,086,454
3,944,668
3,943,058
4,004,894
4,008,694
3,985,315
63,522
69,683
97,969
103,523
114,882
229,235
231,689
272,243
279,736
294,070
294,758
415,044
293,529
352,481
373,166
363,945
356,516
365,805
354,567
435,140
0
498,429
539,438
0
0539,438498,4290435,140354,567365,805356,516363,945373,166352,481293,529415,044294,758294,070279,736272,243231,689229,235114,882103,52397,96969,68363,5223,985,3154,008,6944,004,8943,943,0583,944,6684,086,4542,123,7282,177,5732,016,4242,065,9052,067,9362,063,3752,264,7472,424,8112,572,3752,649,0661,359,3581,363,3721,348,9361,354,5231,407,6401,335,0161,392,871566,19452,88554,74356,67458,68660,58162,47964,28067,05569,31871,58474,07174,25370,985106,381112,135115,89887,522110,503112,690116,528120,901000131,456000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,850
62,933
65,136
70,976
74,597
94,250
96,495
101,249
75,494
74,185
73,280
76,391
122,863
122,036
117,507
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000117,507122,036122,86376,39173,28074,18575,494101,24996,49594,25074,59770,97665,13662,93374,8500000000000000000000000000000000
> Total Liabilities 
0
0
0
283,029
0
0
0
390,867
122,095
147,793
147,077
152,562
226,576
222,210
217,972
210,376
202,233
197,472
184,614
180,226
175,704
113,565
108,800
105,178
94,105
91,813
66,484
60,785
113,528
866,485
840,612
845,201
847,790
918,427
941,798
942,687
1,929,926
1,875,662
2,006,923
1,967,747
1,932,263
1,946,451
1,900,823
1,761,017
1,927,539
1,755,636
3,214,578
2,922,888
2,831,838
2,602,992
2,529,727
2,410,575
2,500,557
2,479,215
2,458,471
2,446,069
2,549,788
2,505,227
2,473,445
2,427,916
2,406,795
2,924,696
2,914,757
2,876,156
2,958,781
9,081,503
8,539,675
8,333,448
8,160,430
7,999,352
7,639,473
7,749,521
7,712,084
7,734,865
7,714,692
7,656,362
7,656,3627,714,6927,734,8657,712,0847,749,5217,639,4737,999,3528,160,4308,333,4488,539,6759,081,5032,958,7812,876,1562,914,7572,924,6962,406,7952,427,9162,473,4452,505,2272,549,7882,446,0692,458,4712,479,2152,500,5572,410,5752,529,7272,602,9922,831,8382,922,8883,214,5781,755,6361,927,5391,761,0171,900,8231,946,4511,932,2631,967,7472,006,9231,875,6621,929,926942,687941,798918,427847,790845,201840,612866,485113,52860,78566,48491,81394,105105,178108,800113,565175,704180,226184,614197,472202,233210,376217,972222,210226,576152,562147,077147,793122,095390,867000283,029000
   > Total Current Liabilities 
0
0
0
23,336
0
0
0
30,520
21,005
31,627
31,360
36,856
74,722
70,303
66,440
173,491
168,530
50,208
38,110
59,241
69,911
56,284
58,100
59,936
61,441
81,317
57,535
52,870
104,584
192,318
178,572
191,538
243,725
184,346
203,359
204,028
238,009
197,768
223,743
216,801
220,582
225,164
340,192
226,642
398,831
226,721
232,859
257,406
392,773
250,393
268,177
293,947
375,619
347,950
341,287
345,487
413,999
369,493
390,439
364,490
396,123
409,960
642,133
653,745
752,093
880,588
735,053
809,303
737,409
705,442
812,954
933,193
908,902
945,265
1,573,329
1,536,692
1,536,6921,573,329945,265908,902933,193812,954705,442737,409809,303735,053880,588752,093653,745642,133409,960396,123364,490390,439369,493413,999345,487341,287347,950375,619293,947268,177250,393392,773257,406232,859226,721398,831226,642340,192225,164220,582216,801223,743197,768238,009204,028203,359184,346243,725191,538178,572192,318104,58452,87057,53581,31761,44159,93658,10056,28469,91159,24138,11050,208168,530173,49166,44070,30374,72236,85631,36031,62721,00530,52000023,336000
       Short-term Debt 
0
0
0
0
0
0
0
2,191
3,104
3,134
2,597
3,459
3,180
6,099
3,265
122,409
123,970
14,638
3,000
33,158
40,731
15,925
7,400
23,414
20,131
36,693
40,709
39,283
3,125
23,750
26,719
29,688
32,656
5,572
5,572
5,572
9,513
9,473
9,444
9,428
9,388
28,478
117,589
37,587
37,592
37,500
36,094
36,094
136,094
36,094
36,094
40,605
45,117
33,387
33,387
33,387
42,056
33,387
45,100
33,387
45,744
33,387
257,077
246,322
262,661
269,464
48,045
31,000
47,155
46,499
45,877
31,000
31,000
47,982
621,229
624,401
624,401621,22947,98231,00031,00045,87746,49947,15531,00048,045269,464262,661246,322257,07733,38745,74433,38745,10033,38742,05633,38733,38733,38745,11740,60536,09436,094136,09436,09436,09437,50037,59237,587117,58928,4789,3889,4289,4449,4739,5135,5725,5725,57232,65629,68826,71923,7503,12539,28340,70936,69320,13123,4147,40015,92540,73133,1583,00014,638123,970122,4093,2656,0993,1803,4592,5973,1343,1042,1910000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
549,976
0
0
0
9,428
0
0
0
37,587
37,592
37,500
2,183,473
36,094
136,094
1,671,894
36,094
40,997
45,117
33,387
33,387
33,387
33,387
33,387
33,387
33,387
33,387
33,387
243,999
246,322
248,613
248,585
31,000
31,000
31,000
31,000
31,000
31,000
31,000
31,000
604,507
604,954
604,954604,50731,00031,00031,00031,00031,00031,00031,00031,000248,585248,613246,322243,99933,38733,38733,38733,38733,38733,38733,38733,38733,38745,11740,99736,0941,671,894136,09436,0942,183,47337,50037,59237,5870009,428000549,97600000000000000000000000000000000000
       Accounts payable 
0
0
0
4,786
0
0
0
5,443
3,145
4,268
2,872
2,856
8,915
8,522
6,614
5,736
4,554
4,074
5,240
2,158
3,885
6,403
3,900
3,049
3,648
4,665
8,463
5,129
13,689
34,505
20,535
15,887
31,634
20,367
22,434
21,005
72,538
32,555
29,671
25,126
27,317
26,409
29,124
21,807
32,622
28,406
17,626
22,415
29,144
28,529
29,972
24,368
46,933
31,379
37,373
40,602
42,669
82,222
70,104
47,545
66,308
50,043
67,063
26,945
77,738
64,826
63,815
100,298
73,336
74,161
102,249
90,758
125,454
98,428
109,850
102,750
102,750109,85098,428125,45490,758102,24974,16173,336100,29863,81564,82677,73826,94567,06350,04366,30847,54570,10482,22242,66940,60237,37331,37946,93324,36829,97228,52929,14422,41517,62628,40632,62221,80729,12426,40927,31725,12629,67132,55572,53821,00522,43420,36731,63415,88720,53534,50513,6895,1298,4634,6653,6483,0493,9006,4033,8852,1585,2404,0744,5545,7366,6148,5228,9152,8562,8724,2683,1455,4430004,786000
       Other Current Liabilities 
0
0
0
18,550
0
0
0
21,464
13,097
22,198
23,892
29,047
61,133
52,252
44,161
33,024
27,401
29,147
27,370
21,250
22,087
30,532
43,388
32,200
36,101
38,593
7,225
7,320
86,632
132,052
129,375
144,825
178,297
157,269
174,215
176,313
154,820
154,602
183,490
181,109
182,739
168,947
192,149
165,878
327,239
159,383
177,640
197,774
218,945
177,195
193,493
220,356
276,592
276,728
264,592
266,084
324,554
249,164
270,515
278,838
279,895
322,897
314,903
377,932
409,321
543,857
620,926
675,912
615,232
583,504
663,957
810,972
752,444
798,851
842,246
774,467
774,467842,246798,851752,444810,972663,957583,504615,232675,912620,926543,857409,321377,932314,903322,897279,895278,838270,515249,164324,554266,084264,592276,728276,592220,356193,493177,195218,945197,774177,640159,383327,239165,878192,149168,947182,739181,109183,490154,602154,820176,313174,215157,269178,297144,825129,375132,05286,6327,3207,22538,59336,10132,20043,38830,53222,08721,25027,37029,14727,40133,02444,16152,25261,13329,04723,89222,19813,09721,46400018,550000
   > Long-term Liabilities 
0
0
0
259,693
0
0
0
360,347
101,090
116,166
115,717
115,706
151,854
151,907
151,532
36,885
33,703
147,264
146,504
120,985
105,793
57,281
50,700
45,242
32,664
10,496
8,949
7,915
8,944
674,167
662,040
653,663
604,065
734,081
738,439
738,659
1,691,917
1,677,894
1,783,180
1,750,946
1,711,681
1,721,287
1,560,631
1,534,375
1,528,708
1,528,915
2,981,719
2,665,482
2,439,065
2,352,599
2,261,550
2,116,628
2,124,938
2,131,265
2,117,184
2,100,582
2,135,789
2,135,734
2,083,006
2,063,426
2,010,672
2,514,736
2,272,624
2,222,411
2,206,688
8,200,915
7,804,622
7,524,145
7,423,021
7,293,910
6,826,519
6,816,328
6,803,182
6,789,600
6,141,363
6,119,670
6,119,6706,141,3636,789,6006,803,1826,816,3286,826,5197,293,9107,423,0217,524,1457,804,6228,200,9152,206,6882,222,4112,272,6242,514,7362,010,6722,063,4262,083,0062,135,7342,135,7892,100,5822,117,1842,131,2652,124,9382,116,6282,261,5502,352,5992,439,0652,665,4822,981,7191,528,9151,528,7081,534,3751,560,6311,721,2871,711,6811,750,9461,783,1801,677,8941,691,917738,659738,439734,081604,065653,663662,040674,1678,9447,9158,94910,49632,66445,24250,70057,281105,793120,985146,504147,26433,70336,885151,532151,907151,854115,706115,717116,166101,090360,347000259,693000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
444,190
435,631
427,073
418,506
546,724
545,564
544,404
1,189,096
1,186,960
1,331,340
1,333,000
1,334,661
1,337,986
1,172,103
1,166,916
1,146,433
1,141,652
2,147,379
1,993,531
1,739,594
1,635,800
1,543,819
1,540,433
1,537,044
1,558,314
1,560,582
1,563,025
1,565,277
1,567,842
1,570,781
1,573,870
1,576,984
2,069,669
1,843,685
1,848,516
1,853,033
6,489,315
6,247,287
6,018,943
5,992,868
5,989,998
5,695,814
5,693,341
5,689,662
5,686,646
0
0
005,686,6465,689,6625,693,3415,695,8145,989,9985,992,8686,018,9436,247,2876,489,3151,853,0331,848,5161,843,6852,069,6691,576,9841,573,8701,570,7811,567,8421,565,2771,563,0251,560,5821,558,3141,537,0441,540,4331,543,8191,635,8001,739,5941,993,5312,147,3791,141,6521,146,4331,166,9161,172,1031,337,9861,334,6611,333,0001,331,3401,186,9601,189,096544,404545,564546,724418,506427,073435,631444,19000000000000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,850
62,933
65,136
70,976
74,597
94,250
96,495
101,249
75,494
74,185
73,280
76,391
122,863
122,036
117,507
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000117,507122,036122,86376,39173,28074,18575,494101,24996,49594,25074,59770,97665,13662,93374,8500000000000000000000000000000000
       Other Liabilities 
0
0
0
833
0
0
0
14,029
13,707
28,370
27,633
27,349
25,246
24,962
24,677
24,393
33,703
32,419
31,141
29,878
25,975
24,587
22,027
20,613
12,095
10,496
8,949
7,915
8,944
44,271
45,490
48,197
16,383
19,613
22,748
25,758
30,828
34,323
38,380
42,892
49,337
56,594
63,312
72,974
82,648
97,357
108,982
115,218
151,433
165,160
176,767
192,723
587,894
572,951
556,602
537,557
416,446
410,286
357,460
337,670
285,131
300,623
287,014
233,860
217,635
1,549,029
1,467,976
1,418,002
1,347,075
1,226,067
1,057,721
1,045,939
0
1,037,407
968,714
0
0968,7141,037,40701,045,9391,057,7211,226,0671,347,0751,418,0021,467,9761,549,029217,635233,860287,014300,623285,131337,670357,460410,286416,446537,557556,602572,951587,894192,723176,767165,160151,433115,218108,98297,35782,64872,97463,31256,59449,33742,89238,38034,32330,82825,75822,74819,61316,38348,19745,49044,2718,9447,9158,94910,49612,09520,61322,02724,58725,97529,87831,14132,41933,70324,39324,67724,96225,24627,34927,63328,37013,70714,029000833000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,496
8,199
7,915
7,630
193,062
188,048
185,169
175,742
174,027
176,128
174,215
477,426
461,759
418,244
379,553
331,898
330,637
328,862
298,206
303,068
293,067
728,239
559,334
570,662
572,109
559,234
399,587
395,713
367,220
337,021
309,097
296,148
283,669
250,167
7,426
165,095
162,376
141,588
130,397
4,724
13,406
1,329,184
12,029
1,222,084
1,096,416
933,670
944,337
932,247
910,724
7,172
0
07,172910,724932,247944,337933,6701,096,4161,222,08412,0291,329,18413,4064,724130,397141,588162,376165,0957,426250,167283,669296,148309,097337,021367,220395,713399,587559,234572,109570,662559,334728,239293,067303,068298,206328,862330,637331,898379,553418,244461,759477,426174,215176,128174,027175,742185,169188,048193,0627,6307,9158,1998,4960000000000000000000000000
> Total Stockholder Equity
0
0
0
-118,248
0
0
0
-176,296
75,815
129,077
111,690
54,992
12,442
-35,619
-38,179
-92,878
-92,296
-88,898
-82,442
-72,830
-68,998
-16,301
-800
30,551
60,073
101,596
141,329
192,788
781,832
831,459
886,087
1,121,292
1,161,900
1,175,453
1,243,701
1,295,534
1,248,893
1,279,691
1,340,523
1,371,144
1,305,276
1,446,768
1,563,463
1,598,646
1,607,440
1,692,458
1,716,003
1,877,339
1,983,986
2,201,032
2,469,297
2,713,097
2,786,571
2,869,752
3,027,317
2,757,422
2,730,447
2,983,434
3,054,405
3,110,981
2,808,500
3,141,805
3,377,201
3,659,745
3,797,689
4,131,490
3,938,477
3,965,191
3,608,487
3,200,781
2,745,194
3,085,734
3,335,041
3,525,675
3,489,373
3,736,997
3,736,9973,489,3733,525,6753,335,0413,085,7342,745,1943,200,7813,608,4873,965,1913,938,4774,131,4903,797,6893,659,7453,377,2013,141,8052,808,5003,110,9813,054,4052,983,4342,730,4472,757,4223,027,3172,869,7522,786,5712,713,0972,469,2972,201,0321,983,9861,877,3391,716,0031,692,4581,607,4401,598,6461,563,4631,446,7681,305,2761,371,1441,340,5231,279,6911,248,8931,295,5341,243,7011,175,4531,161,9001,121,292886,087831,459781,832192,788141,329101,59660,07330,551-800-16,301-68,998-72,830-82,442-88,898-92,296-92,878-38,179-35,61912,44254,992111,690129,07775,815-176,296000-118,248000
   Common Stock
0
0
0
0
0
0
0
0
2
13,176
2
2
2
2
3
3
3
3
3
3
3
4
4
4
4
4
4
4
6
6
6
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61616161616161616161616161616161616161616161616161616161616161616161616161616161616161616166644444443333333222213,176200000000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-419,837
-387,355
-349,882
-322,201
-295,056
-261,847
-61,296
-17,871
-29,264
-2,674
18,532
-74,118
-53,946
-34,666
34,704
95,066
181,828
260,176
302,686
242,441
324,844
315,415
528,907
601,522
690,164
728,123
917,956
929,050
1,000,356
1,128,218
841,050
819,850
1,021,879
1,104,158
0
770,929
878,246
1,026,480
1,159,894
1,281,726
918,410
865,577
830,226
959,347
993,958
974,310
733,586
803,006
811,849
0
0
00811,849803,006733,586974,310993,958959,347830,226865,577918,4101,281,7261,159,8941,026,480878,246770,92901,104,1581,021,879819,850841,0501,128,2181,000,356929,050917,956728,123690,164601,522528,907315,415324,844242,441302,686260,176181,82895,06634,704-34,666-53,946-74,11818,532-2,674-29,264-17,871-61,296-261,847-295,056-322,201-349,882-387,355-419,8370000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
4
0
0
0
12
-1,497
-1,235
1
19
12
26,400
-3
4
25,000
0
0
0
0
0
0
0
0
0
-2
-31
3
-388
13,860
31,046
10,606
19,220
44,622
56,153
70,892
59,946
-57,133
-122,097
-278,584
-248,042
-231,277
-267,472
-222,284
-249,988
-235,376
-317,333
-299,843
-210,249
-158,987
-140,878
-98,768
-168,228
-179,466
-197,791
-220,674
-210,436
-259,442
-223,393
-257,436
-236,109
-187,801
-134,352
-179,428
-190,935
-397,517
-400,360
-590,720
-1,106,029
-1,617,646
-1,125,509
-980,230
-866,823
-1,035,399
-841,674
-841,674-1,035,399-866,823-980,230-1,125,509-1,617,646-1,106,029-590,720-400,360-397,517-190,935-179,428-134,352-187,801-236,109-257,436-223,393-259,442-210,436-220,674-197,791-179,466-168,228-98,768-140,878-158,987-210,249-299,843-317,333-235,376-249,988-222,284-267,472-231,277-248,042-278,584-122,097-57,13359,94670,89256,15344,62219,22010,60631,04613,860-3883-31-200000000025,0004-326,40012191-1,235-1,497120004000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
521,429
528,682
542,697
1,103,498
1,126,371
1,133,542
1,151,010
1,168,633
1,184,965
1,201,221
1,220,317
1,251,587
1,273,159
1,431,790
1,458,005
1,488,262
1,512,450
1,534,032
1,562,900
1,586,750
1,617,069
1,635,431
1,665,232
1,681,774
1,720,584
1,899,628
1,935,486
1,955,756
2,037,091
2,078,032
2,113,630
2,130,738
2,171,458
2,209,156
2,266,026
2,294,474
2,499,135
2,537,989
2,633,670
2,694,858
3,403,482
3,469,884
3,534,792
3,239,327
3,312,319
3,387,997
3,477,124
3,511,732
3,580,115
0
0
003,580,1153,511,7323,477,1243,387,9973,312,3193,239,3273,534,7923,469,8843,403,4822,694,8582,633,6702,537,9892,499,1352,294,4742,266,0262,209,1562,171,4582,130,7382,113,6302,078,0322,037,0911,955,7561,935,4861,899,6281,720,5841,681,7741,665,2321,635,4311,617,0691,586,7501,562,9001,534,0321,512,4501,488,2621,458,0051,431,7901,273,1591,251,5871,220,3171,201,2211,184,9651,168,6331,151,0101,133,5421,126,3711,103,498542,697528,682521,4290000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
610
0
0
0
1,335
274,537
77,356
109,369
371,440
375,607
353,037
405,689
407,923
421,497
422,724
430,852
434,811
437,179
496,263
498,496
505,413
513,108
521,429
528,682
542,697
1,104,024
1,126,897
1,134,068
1,151,481
1,169,104
1,185,436
1,201,692
1,220,788
1,252,058
1,273,630
1,432,261
1,458,476
1,488,733
1,512,921
1,534,503
1,563,371
1,587,222
1,617,541
1,635,903
1,665,704
1,682,246
1,721,056
1,900,100
1,935,958
1,956,228
2,037,563
2,078,504
2,114,102
2,131,210
2,171,930
2,209,628
2,266,498
2,294,946
2,499,607
2,538,461
2,634,142
2,695,330
3,403,954
3,470,356
3,535,264
3,239,799
3,312,791
3,388,469
3,477,596
3,512,204
3,580,588
3,640,413
3,699,954
3,699,9543,640,4133,580,5883,512,2043,477,5963,388,4693,312,7913,239,7993,535,2643,470,3563,403,9542,695,3302,634,1422,538,4612,499,6072,294,9462,266,4982,209,6282,171,9302,131,2102,114,1022,078,5042,037,5631,956,2281,935,9581,900,1001,721,0561,682,2461,665,7041,635,9031,617,5411,587,2221,563,3711,534,5031,512,9211,488,7331,458,4761,432,2611,273,6301,252,0581,220,7881,201,6921,185,4361,169,1041,151,4811,134,0681,126,8971,104,024542,697528,682521,429513,108505,413498,496496,263437,179434,811430,852422,724421,497407,923405,689353,037375,607371,440109,36977,356274,5371,335000610000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,834,204
Cost of Revenue-1,043,861
Gross Profit2,790,3432,790,343
 
Operating Income (+$)
Gross Profit2,790,343
Operating Expense-2,131,063
Operating Income659,280659,280
 
Operating Expense (+$)
Research Development849,658
Selling General Administrative1,330,274
Selling And Marketing Expenses0
Operating Expense2,131,0632,179,932
 
Net Interest Income (+$)
Interest Income0
Interest Expense-351,115
Other Finance Cost-57,876
Net Interest Income-293,239
 
Pretax Income (+$)
Operating Income659,280
Net Interest Income-293,239
Other Non-Operating Income Expenses0
Income Before Tax (EBT)297,9291,020,631
EBIT - interestExpense = 308,165
294,920
765,947
Interest Expense351,115
Earnings Before Interest and Taxes (EBIT)659,280649,044
Earnings Before Interest and Taxes (EBITDA)1,297,976
 
After tax Income (+$)
Income Before Tax297,929
Tax Provision--186,865
Net Income From Continuing Ops79,954484,794
Net Income414,832
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,174,924
Total Other Income/Expenses Net-361,351293,239
 

Technical Analysis of Jazz Pharmaceuticals PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jazz Pharmaceuticals PLC. The general trend of Jazz Pharmaceuticals PLC is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jazz Pharmaceuticals PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jazz Pharmaceuticals PLC.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 111.25 < 113.55 < 115.45.

The bearish price targets are: 106.61.

Tweet this
Jazz Pharmaceuticals PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jazz Pharmaceuticals PLC. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jazz Pharmaceuticals PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jazz Pharmaceuticals PLC. The current macd is -3.12082323.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jazz Pharmaceuticals PLC price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Jazz Pharmaceuticals PLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Jazz Pharmaceuticals PLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Jazz Pharmaceuticals PLC Daily Moving Average Convergence/Divergence (MACD) ChartJazz Pharmaceuticals PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jazz Pharmaceuticals PLC. The current adx is 31.77.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Jazz Pharmaceuticals PLC shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Jazz Pharmaceuticals PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jazz Pharmaceuticals PLC. The current sar is 110.44.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Jazz Pharmaceuticals PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jazz Pharmaceuticals PLC. The current rsi is 32.22. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Jazz Pharmaceuticals PLC Daily Relative Strength Index (RSI) ChartJazz Pharmaceuticals PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jazz Pharmaceuticals PLC. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jazz Pharmaceuticals PLC price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Jazz Pharmaceuticals PLC Daily Stochastic Oscillator ChartJazz Pharmaceuticals PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jazz Pharmaceuticals PLC. The current cci is -94.40797245.

Jazz Pharmaceuticals PLC Daily Commodity Channel Index (CCI) ChartJazz Pharmaceuticals PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jazz Pharmaceuticals PLC. The current cmo is -40.25965655.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Jazz Pharmaceuticals PLC Daily Chande Momentum Oscillator (CMO) ChartJazz Pharmaceuticals PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jazz Pharmaceuticals PLC. The current willr is -91.89722738.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Jazz Pharmaceuticals PLC Daily Williams %R ChartJazz Pharmaceuticals PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jazz Pharmaceuticals PLC. The current atr is 2.42978497.

Jazz Pharmaceuticals PLC Daily Average True Range (ATR) ChartJazz Pharmaceuticals PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jazz Pharmaceuticals PLC. The current obv is -17,763,187.

Jazz Pharmaceuticals PLC Daily On-Balance Volume (OBV) ChartJazz Pharmaceuticals PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jazz Pharmaceuticals PLC. The current mfi is 21.80.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Jazz Pharmaceuticals PLC Daily Money Flow Index (MFI) ChartJazz Pharmaceuticals PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jazz Pharmaceuticals PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Jazz Pharmaceuticals PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jazz Pharmaceuticals PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.215
Ma 20Greater thanMa 50112.656
Ma 50Greater thanMa 100118.634
Ma 100Greater thanMa 200120.370
OpenGreater thanClose108.250
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jazz Pharmaceuticals PLC with someone you think should read this too:
  • Are you bullish or bearish on Jazz Pharmaceuticals PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jazz Pharmaceuticals PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jazz Pharmaceuticals PLC

I send you an email if I find something interesting about Jazz Pharmaceuticals PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Jazz Pharmaceuticals PLC.

Receive notifications about Jazz Pharmaceuticals PLC in your mailbox!